Peripheral BDNF regulation and inflammation in bipolar disorder: a multimodal study
This multimodal study reveals that peripheral BDNF dysregulation in bipolar disorder is a trait-related, multilayer alteration involving reduced expression, positive coupling with inflammation, and adversity-linked epigenetic changes, rather than a linear marker of clinical progression.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Bipolar disorder is a severe mental health condition characterized by dramatic shifts in mood, ranging from periods of intense energy and mania to deep episodes of depression. For decades, scientists have searched for a biological "fingerprint" that could explain why the illness progresses the way it does in some people but not others. A central figure in this search is a protein called brain-derived neurotrophic factor, or BDNF. You can think of BDNF as a fertilizer for the brain; it helps neurons survive, grow, and form new connections, which is essential for learning and emotional stability. In people with bipolar disorder, levels of this protein are often found to be low, suggesting the brain's ability to repair and adapt is compromised. Alongside this, researchers have long suspected that the immune system, which usually fights infection, might be overactive and causing inflammation that harms brain cells. Furthermore, the way genes are switched on or off—often influenced by early life experiences—could be the hidden switch controlling these biological processes. The big question has been whether these biological changes get worse as the illness gets worse, or if they are present from the very beginning and stay the same.
A team of researchers across three psychiatric centers in Italy set out to answer this question by looking at the biology of 134 people with bipolar disorder and 131 healthy individuals. They did not just look at one thing; they took a comprehensive approach, examining the levels of BDNF in the blood, checking the chemical tags on the DNA that control how genes are read, analyzing tiny particles in saliva that carry genetic messages, and measuring various markers of inflammation. They organized the patients into groups based on how long they had been ill and how severe their condition was, hoping to see if the biology matched the clinical stages of the disease.
The study revealed a clear and consistent picture, but it was not the one many had expected. The researchers found that people with bipolar disorder had significantly lower levels of BDNF in their blood compared to healthy people. However, this deficit was not a sign of a disease that was slowly getting worse over time. Instead, the low levels were present even in patients who were in the earliest stages of the illness and did not deepen as the disease progressed. This suggests that the lack of this brain-fertilizing protein is a fundamental trait of the condition, a vulnerability that exists from the start, rather than a result of the illness accumulating damage over the years.
Surprisingly, the researchers found that the low levels of BDNF were not caused by changes in the chemical tags on the DNA that usually silence genes. They checked thirteen different spots on the gene where these tags could sit, but found no difference between patients and healthy people. This means that while the gene is producing less of the protein, the usual mechanism of turning the gene off via DNA methylation is not the culprit. The study also looked at small RNA molecules in saliva that are known to regulate BDNF. While one of these molecules showed a slight increase in patients, the finding was not strong enough to be considered a definitive rule, and the others showed no difference at all.
The researchers did find a strong link between the brain's health and the body's immune system. In the patients, the levels of BDNF moved in the same direction as several immune markers; when one went up, the other tended to go up. This suggests that the brain's ability to repair itself and the body's inflammatory response are tied together in a shared state, rather than inflammation simply suppressing brain health. Among the immune markers, a specific one called interferon-gamma was consistently higher in patients, pointing to a specific type of immune activation rather than a general, chaotic inflammation.
Perhaps the most poignant finding involved the patients' pasts. The study discovered that individuals who reported more severe emotional neglect or abuse during childhood had lower levels of chemical tags at a specific spot on the BDNF gene. This link between early life trauma and a specific biological mark on the gene was strong and clear, suggesting that difficult childhood experiences leave a lasting, measurable imprint on the biology of the brain.
Finally, the study tested the idea that biology could be used to stage the illness. The clinical stages were real; patients in later stages did have more hospitalizations and lower functioning scores. Yet, none of the biological markers measured—neither the BDNF levels, nor the DNA tags, nor the immune markers—followed this clinical progression. They did not get worse as the disease advanced. This indicates that trying to track the stage of bipolar disorder by looking for a single changing molecule in the blood is likely a dead end. Instead, the biology of bipolar disorder appears to be a complex, multi-layered state that is present from the beginning, shaped by early life experiences and linked to the immune system, but not a simple linear path of decline. The researchers conclude that understanding this illness will require looking at a combination of these different signals together, rather than searching for a single magic bullet that changes as the disease progresses.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.